<table>
<thead>
<tr>
<th>Title</th>
<th>Differential effects of fingolimod on B-cell populations in multiple sclerosis (Dissertation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Nakamura, Masakazu</td>
</tr>
<tr>
<td>Citation</td>
<td>Kyoto University (京都大学)</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2014-11-25</td>
</tr>
<tr>
<td>URL</td>
<td><a href="https://dx.doi.org/10.14989/doctor.r12871">https://dx.doi.org/10.14989/doctor.r12871</a></td>
</tr>
<tr>
<td>Type</td>
<td>Thesis or Dissertation</td>
</tr>
<tr>
<td>Textversion</td>
<td>ETD</td>
</tr>
</tbody>
</table>
Differential effects of fingolimod on B-cell populations in multiple sclerosis
Masakazu Nakamura, Takako Matsuoka, Norio Chihara, Sachiko Miyake, Wakiro Sato, Manabu Araki, Tomoko Okamoto, Youwei Lin, Masafumi Ogawa, Miho Murata, Toshimasa Aranami and Takashi Yamamura

Mult Scler published online 13 February 2014
DOI: 10.1177/1352458514523496

The online version of this article can be found at:
http://msj.sagepub.com/content/early/2014/02/18/1352458514523496.citation

Published by:
http://www.sagepublications.com

Additional services and information for Multiple Sclerosis Journal can be found at:

Email Alerts: http://msj.sagepub.com/cgi/alerts
Subscriptions: http://msj.sagepub.com/subscriptions
Reprints: http://www.sagepub.com/journalsReprints.nav
Permissions: http://www.sagepub.com/journalsPermissions.nav

>> OnlineFirst Version of Record - Feb 18, 2014
OnlineFirst Version of Record - Feb 13, 2014
What is This?
Differential effects of fingolimod on B-cell populations in multiple sclerosis

Masakazu Nakamura1,2, Takako Matsuoka1, Norio Chihara1, Sachiko Miyake1,3, Wakiro Sato3,4, Manabu Araki3, Tomoko Okamoto3,4, Youwei Lin1,3,4, Masafumi Ogawa3,4, Miho Murata4, Toshimasa Aranami1,3 and Takashi Yamamura1,3

Abstract

Background: Fingolimod is an oral drug approved for multiple sclerosis (MS) with an ability to trap central memory T cells in secondary lymphoid tissues; however, its variable effectiveness in individual patients indicates the need to evaluate its effects on other lymphoid cells.

Objective: To clarify the effects of fingolimod on B-cell populations in patients with MS.

Methods: We analysed blood samples from 9 fingolimod-treated and 19 control patients with MS by flow cytometry, to determine the frequencies and activation states of naive B cells, memory B cells, and plasmablasts.

Results: The frequencies of each B-cell population in peripheral blood mononuclear cells (PBMC) were greatly reduced 2 weeks after starting fingolimod treatment. Detailed analysis revealed a significant reduction in activated memory B cells (CD38int-high), particularly those expressing Ki-67, a marker of cell proliferation. Also, we noted an increased proportion of activated plasmablasts (CD138+) among whole plasmablasts, in the patients treated with fingolimod.

Conclusions: The marked reduction of Ki-67+ memory B cells may be directly linked with the effectiveness of fingolimod in treating MS. In contrast, the relative resistance of CD138+ plasmablasts to fingolimod may be of relevance for understanding the differential effectiveness of fingolimod in individual patients.

Keywords

B cells, CD38, CD138, fingolimod, memory B cell, multiple sclerosis, plasmablast, proliferation, resistance, sphingosine 1-phosphate receptor 1

Introduction

It is currently assumed that a large proportion of autoreactive T cells in multiple sclerosis (MS) is derived from a pool of CCR7+ central memory T cells that are passing through the secondary lymphoid tissues (SLT).1 Accordingly, egress of the T cells from the SLT represents a key process in MS pathogenesis. This process follows a rule of chemotaxis, in which the sphingosine 1-phosphate (S1P) receptor 1 (S1P1) expressed by lymphocytes is critically involved.2 Fingolimod, an oral drug for treating relapsing–remitting MS (RRMS), serves as a functional antagonist for S1P1: Fingolimod induces internalisation and degradation of S1P1 in lymphocytes, causing the lymphocytes to lose the ability to respond to S1P and consequently, to become trapped in the SLT.3 Analysis of large cohorts of patients with RRMS demonstrate the overall effectiveness of fingolimod in reducing the annualised relapse rate (ARR), as well as the appearance of new brain lesions in the patients’ magnetic resonance imaging (MRI) scans.4,5

The number of central memory interleukin 17-producing CD4+ T cells (Th17 cells) is reduced in the peripheral blood of fingolimod-treated patients. This is now being interpreted as a major mechanism of drug action;6 however, fingolimod is not able to prevent relapses nor exhibit
appreciable effectiveness in all patients. In fact, recent case reports document the presence of fingolimod-treated MS patients who have developed tumefactive brain lesions, after receiving fingolimod.7–10 Moreover, clinical worsening accompanied by large brain lesions is described in patients with neuromyelitis optica (NMO), within months of starting fingolimod.11,12 Our current understanding of fingolimod-related biology therefore remains incomplete, particularly regarding differential effectiveness in individual patients.

Not only the presence of clonally-expanded B cells in the central nervous system (CNS),13,14 but the efficacy of the anti-CD20 monoclonal antibody (mAb) rituximab15 rationally indicates the involvement of B cells in the pathogenesis of MS. Therefore, B-cell migration can serve as a therapeutic target in MS, so we were prompted to investigate whether inhibition of B-cell migration may explain the differential effectiveness of fingolimod. Because the effects of fingolimod on B cells in MS have not been fully characterised,16 we analysed the alterations of B-cell populations in fingolimod-treated RRMS patients by flow cytometry, measuring the frequencies and activation states of their peripheral blood B-cell populations.

Materials and methods

Patients and sample collection

The following subjects were enrolled in the Multiple Sclerosis Clinic of the National Centre of Neurology and Psychiatry (NCNP) in Japan:

(a) Fingolimod-naïve patients with RRMS (n = 9);
(b) RRMS patients who were treated with other disease-modifying treatments (DMTs) or corticosteroids (n = 19); and
(c) Healthy donors (n = 3).

All MS patients fulfilled the revised McDonald criteria.17 Fingolimod (0.5 mg once/day) was administered to nine fingolimod-naïve patients. These patient’s blood samples were collected before and 2 weeks after initiating fingolimod therapy. Most of these patients discontinued other DMTs at least 2 weeks before entry into the study, due to non-responsiveness to their DMT treatment or due to adverse events. The absence of serum anti-aquaporin 4 (AQP4)-Ab was confirmed by cell-based assays.18,19 Upon MRI, no patient showed longitudinally-extensive spinal cord lesions extending over three or more vertebrae. The clinical data of these nine patients are summarised in Table 1.

Control blood samples were collected from 19 patients with RRMS (mean age ± SD: 41.8 ± 13.8 years; female:male ratio: 15:4) who had not been exposed to fingolimod before nor during the study. The three healthy donors were males (mean age ± SD: 40.0 ± 3.6 years). This study was approved by the Ethics Committee of the NCNP. We obtained written informed consent from all subjects.

Reagents

The following fluorescence- or biotin-labelled mAbs were used: anti-CD19-allophycocyanin (APC)-cyanine 7 (Cy7), anti-CD27-V500 and anti-CD27-phycoerythrin (PE)-Cy7 (BD Biosciences, San Jose, CA, USA); anti-CD180-PE and anti-CCR7-fluorescein isothiocyanate (FITC) (BD Pharmingen, San Jose, CA, USA); anti-CD38-FITC, anti-CD3-FITC and mouse IgG1-FITC (Beckman Coulter, Brea, CA, USA); anti-CD138-APC, mouse IgG1κ-APC, anti-HLA-DR-Pacific Blue, mouse IgG2Aκ-Pacific Blue, anti-CD183 (CXCR3)-peridinin-chlorophyll-protein (PerCp)-cyanine 5.5 (Cy5.5), mouse IgG1κ-PerCp-Cy5.5, anti-CD38-APC, anti-CD38-PerCp-Cy5.5, anti-CD14-Pacific Blue, anti-Ki-67-Brilliant Violet, mouse IgG1κ-Brilliant Violet and streptavidin-PE-Cy7 (BioLegend, San

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Duration (years)</th>
<th>Relapse frequency (last 2 yrs)</th>
<th>EDSS</th>
<th>DMT before initiation of fingolimod</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>34</td>
<td>7</td>
<td>5</td>
<td>1.5</td>
<td>IFNβ1a + PSL</td>
<td>Asthma</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>43</td>
<td>6</td>
<td>2</td>
<td>2.5</td>
<td>PSL</td>
<td>Graves’ disease</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>39</td>
<td>5</td>
<td>1</td>
<td>3.5</td>
<td>None</td>
<td>Depression</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>41</td>
<td>13</td>
<td>1</td>
<td>3.5</td>
<td>IFNβ1b</td>
<td>None</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>29</td>
<td>2</td>
<td>3</td>
<td>2.0</td>
<td>IFNβ1b</td>
<td>Pectus excavatum</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>41</td>
<td>24</td>
<td>6</td>
<td>3.5</td>
<td>IFNβ1b → GA → Dex</td>
<td>Depression</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>56</td>
<td>16</td>
<td>2</td>
<td>5.5</td>
<td>IFNβ1b → IFNβ1b + PSL →</td>
<td>Osteoporosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IFNβ1a + AZP</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>41</td>
<td>9</td>
<td>2</td>
<td>4.0</td>
<td>IFNβ1b → IFNβ1a</td>
<td>Depression</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>60</td>
<td>20</td>
<td>1</td>
<td>3.5</td>
<td>AZP → MZR → IFNβ1b</td>
<td>None</td>
</tr>
<tr>
<td>mean ± SD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>42.7 ± 9.8</td>
<td>11.3 ± 7.4</td>
<td>2.5 ± 1.8</td>
</tr>
</tbody>
</table>

AZP: Azathioprine; Dex: dexamethasone; DMT: disease-modifying treatment; EDSS: Expanded Disability Status Scale; F: female; GA: glatiramer acetate; IFN: interferon; M: male; MZR: mizoribine; PSL: prednisolone.

Table 1. Clinical data of the patients in this study.
and plasmablasts (PBs), CD19+CD27+CD180–CD38high.

**Cell preparation and flow cytometry**

Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation, using Ficoll–Paque Plus (GE Healthcare Bioscience, Oakville, ON, Canada). B-cell populations were defined in reference to our previous paper, as follows: total B cells, CD19+; naïve B cells (nBs), CD19+CD27; memory B cells (mBs), CD19+CD27-CD180+; and plasmablasts (PBs), CD19+CD27-CD180+CD38high.

To evaluate the frequency and activation state of each B-cell population, PBMC were stained with anti-CD19-APC-Cy7, anti-CD27-V500, anti-CD38-PerCp-Cy5.5, anti-CXCR4-biotin, streptavidin-PE-Cy7 and anti-HLA-DR-Pacific Blue. To assess the expression of CCR7 in each B cell population, PBMC were stained with anti-CD19-APC-Cy7, anti-CD27-PE-Cy7, anti-CD38-APC, anti-CD180-PE and anti-CCR7-FITC.

For examining Ki-67 expression in each B-cell population, PBMC were stained with anti-CD19-APC-Cy7, anti-CD27-PE-Cy7, anti-CD38-PerCp-Cy5.5, anti-CD14-APC, and anti-CD138-APC, then fixed in phosphate-buffered saline (PBS) containing 2% paraformaldehyde and permeabilised with 0.1% saponin. Subsequently, these cells were stained with anti-Ki-67-Brilliant Violet. We used the appropriate isotype control antibodies as negative controls for each staining. At the end of the incubation, the cells were washed and resuspended in PBS supplemented with 0.5% bovine serum albumin (BSA) and analysed by FACS Canto II (BD Biosciences), according to the manufacturer’s instructions.

**Cell sorting**

PBMC were labelled with CD3 and CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and then separated into positive and negative fractions by AutoMACS (Miltenyi Biotec). The positive fraction was stained with anti-CD3-FITC and anti-CD14-Pacific Blue, whereas the negative fraction was stained in phosphate-buffered saline (PBS) containing 2% paraformaldehyde and permeabilised with 0.1% saponin. Subsequently, these cells were stained with anti-CD19-APC-Cy7, anti-CD27-PE-Cy7, anti-CD38-APC, anti-CD180-PE, and anti-CCR7-FITC.

To assess the expression of CCR7 in each B cell population, PBMC were stained with anti-CD19-APC-Cy7, anti-CD27-PE-Cy7, anti-CD38-APC, anti-CD180-PE and anti-CCR7-FITC.

For examining Ki-67 expression in each B-cell population, PBMC were stained with anti-CD19-APC-Cy7, anti-CD27-PE-Cy7, anti-CD38-PerCp-Cy5.5, anti-CD14-APC, and anti-CD138-APC, then fixed in phosphate-buffered saline (PBS) containing 2% paraformaldehyde and permeabilised with 0.1% saponin. Subsequently, these cells were stained with anti-Ki-67-Brilliant Violet. We used the appropriate isotype control antibodies as negative controls for each staining. At the end of the incubation, the cells were washed and resuspended in PBS supplemented with 0.5% bovine serum albumin (BSA) and analysed by FACS Canto II (BD Biosciences), according to the manufacturer’s instructions.

**Quantitative real-time PCR**

Messenger ribonucleic acid (mRNA) was prepared from the sorted cells using the RNeasy Kit (Qiagen, Tokyo, Japan), further treated with DNase using the RNase-Free DNase Set (Qiagen), and reverse-transcribed to complementary DNA (cDNA) using the cDNA Synthesis Kit (Takara Bio, Shiga, Japan). We performed polymerase chain reaction (PCR) using iQ SYBR Green Supermix (Takara Bio) on a LightCycler (Roche Diagnostics, Indianapolis, IN, USA). RNA levels were normalised to endogenous β-actin (ACTB) for each sample. The following primers were used: S1P1 forward, CGAGAGCACCAGCAGTCAG; and S1P1 reverse, AGAGCTTCACTGGCTTCAG.

**Data analysis and statistics**

We used Diva software (BD Biosciences) to analyse our flow cytometry data. We performed the statistical analysis with Prism software (GraphPad Software, San Diego, CA, USA). Paired or unpaired t-tests were used once the normality of the data was confirmed by the Kolmogorov-Smirnov test. Otherwise, the Wilcoxon signed-rank test or the Mann-Whitney U-test was used, as appropriate. One-way analysis of variance (ANOVA) was used to compare data from more than two groups. If the one-way ANOVA was significant, we performed post hoc pairwise comparisons using Tukey’s test. A p value < 0.05 was considered statistically significant.

**Results**

**B-cell populations express S1P1 mRNA**

First, we used flow cytometry to examine S1P1 expression on the surfaces of the B-cell populations; however, surface S1P1 was hardly detected (data not shown). This is probably because of its internalisation following S1P binding. In support of this, it is known that S1P is abundantly present in peripheral blood. Thus, we measured S1P1 mRNA in purified lymphocyte populations from the PBMCs of three healthy donors. Each B-cell population was identified by flow cytometry, as shown in Figure 1(a). We found that comparable levels of S1P1 mRNA were expressed in T cells, nBs and mBs. In comparison, PBs expressed a significantly lower level of S1P1, and S1P1 expression in monocytes was virtually absent (Figure 1(b)). Of note, a lower S1P1 expression by PBs, as compared with other B cell populations, is also described in mice. These S1P1 mRNA expression profiles suggested that not only T cells, but B-cell migration, could also be influenced by fingolimod.

Next, we measured the frequencies of the B-cell populations in the PBMCs from nine patients with RRMS, before and 2 weeks after starting fingolimod. Results of flow cytometry showed that the frequencies of nBs, mBs and PBs among PBMCs were significantly decreased after initiating fingolimod treatment (Figure 1(c)). We confirmed that the absolute numbers of each population in the peripheral blood were also significantly decreased after starting fingolimod (Figure 1(d)). The mean decrease rate ± SD of each cell population was calculated based on the absolute cell number, giving the following results: total B cells, 87.6 ± 5.8%; nBs, 88.1 ± 6.0%; mBs, 85.4 ± 9.1% and PBs, 89.8 ± 5.8%.
Figure 1. Frequency and absolute number of each B-cell population found in peripheral blood from MS patients.

(a) Representative flow cytometry scheme to analyse B-cell populations in PBMC. The PBMC were simultaneously stained with fluorescence-conjugated anti-CD19, -CD27, -CD38 and -CD180 mAbs. The gate for CD19^CD27^ nBs is shown in the left panel. The CD19^CD27^ fraction partitioned in the left panel was analysed for CD180 and CD38 expression to specify CD180^+ cells (mBs), and for CD180^−CD38^high cells (PBs) in the right panel. Values represent frequencies of B-cell populations in PBMC. Total CD19^+ B cell counts were calculated by summing the frequencies of the partitioned populations in the left panel. (b) Each B-cell population, CD3^+ T cells and CD14^+ monocytes in PBMCs from three healthy donors were sorted by FACS, and S1P1 mRNA expression levels were determined by quantitative RT-PCR. Data were normalised to the amount of ACTB for each sample. Data are represented as mean relative expression ± SD. *p < 0.05 by one-way ANOVA and post hoc Tukey’s test. (c), (d), and (e) Data shown are the frequencies of B-cell populations in PBMC (c), the absolute numbers of B cell populations in peripheral blood (d) and the frequencies of B-cell populations in CD19^+ B cells (e) from nine patients with MS before (pre) and 2 weeks after (2 wk) initiating fingolimod. Data from the same patients are connected with lines.

p < 0.05 by Wilcoxon signed-rank test.

p < 0.05 by paired t-test.

ACTB: endogenous beta actin; ANOVA: analysis of variance; FACS: Fluorescence-activated cell sorting; mAbs: monoclonal antibodies; mBs: memory B cells; mono: monocytes; mRNA: messenger ribonucleic acid; MS: multiple sclerosis; nBs: naïve B cells; NS: not statistically significant; PBMC: peripheral blood mononuclear cells; PBs: plasmablasts; pre: before treatment; RT-PCR: reverse transcriptase - polymer chain reaction; S1P1: sphingosine 1 phosphate receptor 1; T: T cells; 2 wk: 2 weeks after treatment initiation.
significantly higher frequency of Ki-67 + cells than did CD38high mB subpopulations. We found that the CD38 high mBs expressed CCR7, whereas only a small percentage of PBs expresses CCR7 (Supplementary Figure 1)). Consistently, the frequency of each B-cell population within CD19+ B cells was not significantly altered in the fingolimod-treated patients (Figure 1(e)).

CD38int and CD38high-activated memory B cells are preferentially decreased in fingolimod-treated patients

We next assessed mBs, which are assumed to play an important role in MS.22,23 To evaluate the effects of fingolimod on the activation state of mBs, we first analysed CD38 expression of mBs in the nine patients, before and after initiating fingolimod. CD38 is a marker that is upregulated upon B-cell activation.24 We found that mBs could be classified into three subpopulations according to CD38 expression levels (CD38low, CD38int and CD38high). Notably, frequencies of CD38int and CD38high mBs were significantly decreased 2 weeks after initiating fingolimod, whereas the frequency of the CD38low subpopulation significantly decreased 2 weeks after initiating fingolimod, whereas the frequency of the CD38low subpopulation became significantly increased (Figure 2(a) and (b)).

We further examined the expression of another activation marker, HLA-DR, within the CD38low, CD38int and CD38high mB subpopulations. We found that the CD38high subpopulation expressed a significantly higher level of HLA-DR, compared with the CD38low mB population, as assessed by mean fluorescence intensities (MFIs) (Figure 2(c) and (d)). Although not statistically significant, HLA-DR expression in the CD38int subpopulation was intermediate, compared with that in the CD38low mB subpopulation. We also found that the MFIs of forward scatter (FSC), which reflects cell size, were significantly higher in the CD38high subpopulation, compared with the CD38low and CD38int subpopulations (Figure 2(c) and (d)). These findings suggest that CD38high mBs may contain a larger number of recently-activated elastic cells.

*Fingolimod reduced Ki-67+ recently-activated memory B cells in peripheral blood*

The nuclear antigen Ki-67 is exclusively expressed in the active stages of the cell cycle (G1, S, G2 and M phases),25 and Ki-67+ circulating immune cells are considered to be recently activated cells that have just egressed from the SLT. To clarify whether CD38high and CD38int mB subpopulations are enriched for recently-activated cells, we examined the frequency of Ki-67+ cells in each mB subpopulation, in the six MS patients who were not treated with fingolimod. This analysis revealed that CD38high mBs contained a significantly higher frequency of Ki-67+ cells than did CD38low and CD38int mBs, and that CD38int mBs were likely to contain a higher frequency of Ki-67+ cells than the CD38low mBs (Figure 3(a) and (b)). In addition, we compared the frequency of Ki-67+ cells in each mB subpopulation, between fingolimod-treated (n = 5) and -untreated control patients (n = 6), and found that CD38int and CD38high mBs of the fingolimod-treated patients contained a significantly lower percentage of Ki-67+ cells compared with those of the untreated patients (Figure 3(c)). These findings suggest that recently activated mBs are enriched in CD38int and CD38high subpopulations and that fingolimod efficiently blocks the egress of these cells from the SLT into the peripheral circulation.

The CD138+ subpopulation in plasmablasts is relatively resistant to fingolimod

Finally, we analysed alterations of PBs by fingolimod in more detail. As PBs serve as migratory B cells that produce pathogenic autoantibody directed against AQP4,19 their role in the antibody-mediated pathology is being considered also in the pathogenesis of MS. Notably, CD138 expression appears to separate PB subpopulations that could become differentially altered during the inflammatory process. In fact, CD138+ PBs have a higher potential to migrate to inflamed tissues than CD138– PBs.26 Moreover, as has recently been reported by us, CD138+HLA-DR+ PBs are selectively enriched in the cerebrospinal fluid (CSF) during relapse of NMO, and the CD138+HLA-DR+ PBs migrating to the CSF express CXCR3.27 Therefore, we compared the frequencies of CD138+ cells in PBs, as well as their expression of HLA-DR and CXCR3, before and after fingolimod treatment.

We found that the frequencies of CD138+ PBs among total PBs were significantly increased after fingolimod initiation (Figure 4(a) and (b)); however, the absolute numbers of both subpopulations decreased, implying that CD138+ PBs are relatively resistant to fingolimod, compared with CD138– PBs (Supplementary Figure 2(a) and (b)). After initiating fingolimod, CD138+ PBs showed lower expression of HLA-DR, whereas the percentages of CXCR3+ cells remained unchanged (Figure 4(c) – (e)). In contrast, fingolimod treatment did not significantly reduce the expression level of HLA-DR among CD138– PBs. More interestingly, CD138+ PBs became more enriched with CXCR3+ cells after initiating fingolimod (Figure 4(c) – (e)). The definition of PBs as CD19+CD27+CD180–CD38high cells in this study was modified to efficiently specify autoantibody-producing cells;19 however, adopting a more commonly used definition of PBs as CD19+CD27+CD38high cells did not alter the results (Supplementary Figure 3(a) – (e)).

Discussion

Previous studies show that fingolimod markedly decreases the number of T and B cells in the peripheral blood, without...
Figure 2. Frequency and activation state of each mB subpopulation in the peripheral blood of MS patients.

(a) Representative histograms of CD38 expression in mB of peripheral blood from a fingolimod-treated patient. Upper (pre) and lower (2wk) panels show the histograms before and 2 weeks after fingolimod initiation, respectively. The two values above each histogram indicate frequencies of the mB subpopulations with intermediate (CD38int, left) and high (CD38high, right) CD38 expression. (b) Data shown are frequencies of mB subpopulations, classified by CD38 expression levels (CD38low (left panel), CD38int (middle panel) and CD38high (right panel)), in the peripheral blood from nine patients with MS, before (pre) and 2 weeks after (2wk) fingolimod initiation. Data from the same patients are connected with lines. *p < 0.05 by Wilcoxon signed-rank test. (c) Representative histograms of HLA-DR (left column) and FSC (right column) expression in each mB subpopulation (CD38low (upper row), CD38int (middle row) and CD38high (lower row)) of peripheral blood from a patient with MS, before fingolimod initiation. Values represent MFIs of HLA-DR and FSC. (d) Data shown are MFI of HLA-DR (left panel) and FSC (right panel) in mB subpopulations (CD38low, CD38int and CD38high) of peripheral blood from nine patients with MS, before fingolimod treatment. Data are represented as mean ± SD. *p < 0.05 by one-way ANOVA and post hoc Tukey’s test.

ANOVA: analysis of variance; FSC: forward scatter; HLA: human leukocyte antigen; mB: memory B cells; MFI: mean fluorescence intensity; MS: multiple sclerosis; pre: before treatment; 2wk: 2 weeks after treatment initiation.
Figure 3. Ki-67 expression in mB subpopulations of peripheral blood from MS patients.
(a) Representative flow cytometry analyses of intracellular Ki-67 expression in mB subpopulations (CD38low (left panel), CD38int (middle panel), and CD38high (right panel)) of peripheral blood from an untreated patient with MS. Each mB subpopulation was analysed for FSC and Ki-67 expression. Values in each plot represent frequency of Ki-67+ cells in each mB subpopulation. (b) Frequency of Ki-67+ cells in each mB subpopulation of peripheral blood from six untreated patients with MS. Data are represented as mean ± SD. *p < 0.05 by one-way ANOVA and post hoc Tukey’s test. (c) Frequency of the Ki-67+ population in each mB subpopulation (CD38low (left panel), CD38int (middle panel), and CD38high (right panel)) is compared between untreated patients with MS (control; n = 6) and fingolimod-treated patients with MS (Fingolimod; n = 5). Mean duration with fingolimod treatment ± SD is 15.8 ± 8.8 (6 to 30) weeks. Data are represented as mean ± SD. *p < 0.05 by unpaired t-test.

FSC: forward scatter; Ki-67: a marker present only during cell growth or proliferation; mB: memory B cells; MS: multiple sclerosis; NS: not statistically significant.

affecting the total numbers of monocytes and natural killer (NK) cells. Furthermore, in MS, fingolimod selectively reduces naïve T cells, as well as CD4+ central memory T cells that are enriched for Th17 cells. In addition, fingolimod treatment may induce a relative increase in CD27+CD28−CD8+ T cells and a decrease in CD56brightCD62L+CCR7+ NK cells.

The role of autoreactive CD4+ T cells in MS pathogenesis has been emphasised over decades. In contrast, B-cell involvement in MS was highlighted lately, after the clinical effectiveness of rituximab was demonstrated in RRMS patients. Rituximab’s effectiveness in MS may result from the depletion of autoantibody-producing B cells, but it can also be explained by depletion of B cells that are able to induce or support activation of autoreactive T cells. In fact, B cells exhibit the ability to present antigen to T cells, and mBs are more capable than nBs of supporting the proliferation of neuroantigen-specific CD4+ T cells, in vitro. The presence of oligoclonal bands in the CSF suggests local production of antibodies within the CNS. Consistent with this, brain lesions and CSF of patients with MS contain clonally-expanded B cells. These results collectively support the postulate that mBs can potentially trigger the inflammation of MS, either via autoantibody production or via autoantigen presentation to autoreactive T cells.

The focus of this study is to investigate the alterations of peripheral blood B-cell types in fingolimod-treated patients with RRMS. We showed that activated CD38int and CD38high mB subpopulations were highly susceptible to
Figure 4. Phenotypic alteration of the remaining PBs in peripheral blood following fingolimod treatment. (a) Representative dot plots of CD19+CD27+CD180–CD38high PB, analysed for CD19 and CD138 expression before (pre) and 2 weeks after (2wk) fingolimod initiation. Values represent frequencies of the CD138+ subpopulation in total PB. (b) Data are frequencies of the CD138+ subpopulation in total PB of peripheral blood from nine patients with MS before (pre) and 2 weeks after (2wk) fingolimod initiation. Data from the same patients are connected with lines. *p < 0.05 by Wilcoxon signed-rank test. (c) Data are representative histograms of HLA-DR expression in CD138+ and CD138– PB of peripheral blood, from a patient with MS before (pre) and 2 weeks after (2wk) fingolimod initiation. Values represent MFI of HLA-DR. (d) Data are MFI of HLA-DR in CD138+ and CD138– PB of peripheral blood from nine patients with MS, before (pre) and 2 weeks after (2wk) fingolimod initiation. Data from the same patients are connected with lines. *p < 0.05 by paired t-test. (e) Data are frequencies of CXCR3+ cells in CD138+ PB and CD138– PB of peripheral blood from nine patients with MS before (pre) and 2 weeks after (2wk) fingolimod initiation. Data from the same patients are connected with lines. *p < 0.05 by Wilcoxon signed-rank test. MFI: mean fluorescence intensity; MS: multiple sclerosis; NS: not statistically significant; PB: plasmablast; pre: before treatment; 2wk: after 2 weeks of treatment.
fingolimod, as indicated by their reduction in the peripheral blood following fingolimod treatment. It is demonstrated in mice that surface expression levels of S1P1 on B cells in the SLT are controlled by transcription levels and CD69-mediated internalisation of S1P1. Stimulation of B-cell receptors induces not only a cessation of S1P1 transcription, but also an upregulation of CD69. Both of these changes reduce the expression levels of surface S1P1 in the SLT to some extent.2

Although we were not able to directly analyse B cells in the SLT of the patients, we speculated that surface S1P1 expression on mBs within the SLT in human may also decrease greatly, following antigen activation and exposure to fingolimod, which would result in these B lymphocytes having a reduced responsiveness to S1P. In fact, the activated mB subpopulations that we isolated from the patients’ peripheral blood, in particular CD38high mB, were found to contain a substantial proportion of Ki-67+ cells (Figure 3(a) and (b)). We confirmed that the proportions of Ki-67+ cells in the activated CD38int and CD38high mB subpopulations were significantly decreased following fingolimod treatment, suggesting that recently-activated cells were selectively trapped in the SLT following fingolimod treatment. Because activation of autoreactive mBs in the SLT followed by their migration to the CNS could trigger a relapse of RRMS,35 we assumed that inhibition of activated mB cell egress from the SLT was at least partly involved in the reduced relapses of RRMS after fingolimod treatment.

We also identified a PB subpopulation that is relatively resistant to fingolimod as being CD138+ PBs. The frequency of the CD138+ subpopulation in the total PBs, and that of CXCR3+ cells in CD138+ PBs, was significantly increased by fingolimod treatment. Of note, the CD138+CXCR3+ PBs are enriched in the CSF of NMO during relapse,27 and fingolimod could induce exacerbation of NMO, accompanied by the appearance of large brain lesions.11,12 Although knowledge on the biology of PBs is limited, the percentages of CCR7+ cells are much lower as compared with nBs or mBs, indicating that fingolimod may differentially alter the in vivo migration of PBs and other B cells.

It is of relevance to note that despite reductions of circulating lymphocytes, RRMS patients receiving fingolimod may develop clinical relapses. These relapses are not always mild, but could be serious and accompany huge brain lesions.3–10 Although the trapping of regulatory lymphocytes in the SLT8,9 or the enrichment for CD45RO−CCR7−CD8+ T cells in the CSF7 is proposed as a possible mechanism for formation of tumefactive brain lesions, we were very curious to know if the increased proportion of CD138+ PBs over other lymphocytes in the peripheral blood might influence the character of the CNS pathology and induce large demyelinating lesions. In fact, it was recently reported that CD45+CD19+CD138+ PBs are relatively enriched in the CSF of fingolimod-treated MS patients,16 raising the possibility that the dominance of CD138+ PBs in the peripheral blood is preserved or even promoted in the CNS of patients with MS who develop tumefactive brain lesions7–10 and NMO patients who deteriorate11,12 after being treated with fingolimod. Therefore, resistance of activated PBs in fingolimod-treated patients with MS or NMO may give us a clue to understanding the individual patients’ differences regarding the effectiveness of fingolimod therapy.

Acknowledgements
We thank Toshiyuki Takahashi at the Department of Neurology, Tohoku University, for examining serum anti-AQP4-Abs in our patients. We also thank Hiromi Yamaguchi, Yasuko Hirakawa, and Tomoko Ozawa for their technical support.

Conflict of interest
The authors declare that there are no conflicts of interest.

Funding
This work was supported by the Ministry of Health, Labour and Welfare of Japan (grant on intractable neuroimmunological diseases number H23-nanchi-Ippan-017); and the Japanese Society for the Promotion of Science (grant number: S24229006).

References


